1stOncology™: Cancer Intelligence Service – Page 86 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

NeoGenomics Reports Second Quarter 2026 Results

On July 28, 2026 NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, reported its second-quarter results for the period ended June 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Financial Highlights

For the three-month period ended June 30, 2026, as compared to the same period in 2025:

Increased total revenue by 11% to $202 million
Increased clinical revenue by 14% to $187 million driven by robust NGS growth of 26%
Recorded GAAP net income of $2 million, including a gain on extinguishment of debt of $11 million
Delivered adjusted EBITDA(1) of $14 million, an increase of 36%
Generated $20 million from cash from operations to end the quarter with $146 million of cash, cash equivalents, and short-term investments
Business Highlights

Sharpened commercial strategy and go-to-market execution by launching a dedicated pathology and oncology commercial team
Submitted new RaDaR ST evidence to MolDx supporting Medicare reimbursement for a new indication. This marks the third RaDaR ST submission to MolDx pending approval
Strengthened capital structure through the completion of a $316 million private offering of 0.75% convertible senior notes due 2032
Finalized a civil settlement with the Department of Justice resolving a self-disclosed matter and investigation concerning consulting services provided by the Company
"Our second quarter results reflect the consistent operating and financial performance investors expect from this team," said Tony Zook, Chief Executive Officer of NeoGenomics. "Revenue growth of 11% year-over-year exceeded our outlook, with NGS revenue growth of 26% reflecting a continued mix shift to more advanced testing modalities. This revenue growth is being coupled with our focus on disciplined margin expansion, as evidenced by adjusted EBITDA increasing by 36%. Looking ahead, I remain confident that we are well positioned to deliver long-term profitable growth, while investing in our business and expanding our suite of on-market testing solutions for patients and providers."

Second-Quarter Results

Consolidated revenue for the second quarter of 2026 was $202 million, an increase of 11% over the same period in 2025. Clinical volume increased by 2%, while average revenue per clinical test increased by 12% to $515.

Consolidated gross profit for the second quarter of 2026 was $92 million, an increase of 19% compared to the second quarter of 2025. Consolidated gross profit margin, including amortization of acquired intangible assets and stock-based compensation expense, was 46%. Adjusted Gross Profit Margin(1), excluding amortization of acquired intangible assets and stock-based compensation expense, was 48%, an increase of 260 bps versus the same period in 2025.

Operating expenses for the second quarter of 2026 were $102 million, a decrease of $23 million, or 19%, compared to the second quarter of 2025. The decrease in operating expenses was primarily due to $20 million of impairment charges taken in the second quarter of 2025.

Net income for the quarter was $2 million compared to net loss of $45 million for the second quarter of 2025. Net income for the quarter includes a gain on extinguishment of debt of $11 million.

Adjusted EBITDA(1) for the second quarter of 2026 increased by 36% to $14 million, compared to $11 million in the second quarter of 2025. Adjusted Net Income(1) was $7 million compared to Adjusted Net Income(1) of $4 million in the second quarter of 2025.

Cash and cash equivalents totaled $146 million at quarter end. This reflects the net effects from the completion of the company’s $316 million private offering of 0.75% convertible senior notes due 2032. As part of the transaction, the Company repurchased approximately $276 million aggregate principal amount of the Company’s existing 0.25% convertible senior notes due 2028 and entry into capped call transactions intended to reduce potential dilution upon conversion. Company also repurchased shares of its common stock for an aggregate purchase price of $25 million.

(1)

The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this press release entitled "Use of Non-GAAP Financial Measures." See also the tables reconciling such measures to their closest GAAP equivalent.

2026 Financial Guidance

The Company is revising its full-year 2026 guidance, as shown below (in millions).

FY 2025

Previous
FY 2026 Guidance

Updated
FY 2026 Guidance

YOY % Change from
FY 2025

(in millions)

Actual

Low

High

Low

High

Low

High

Consolidated revenue

$727

$797

$803

$802

$806

10%

11%

Net loss

$(108)

$(63)

$(50)

$(42)

$(34)

61%

69%

Adjusted EBITDA

$43

$55

$57

$56

$58

29%

34%

Conference Call

The Company has scheduled a webcast and conference call to discuss its second quarter 2026 results on Tuesday, July 28, 2026 at 4:30 p.m. Eastern Time. To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 968605. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.

(Press release, NeoGenomics Laboratories, JUL 28, 2026, View Source [SID1234669472])

CORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer Therapeutics

On July 28, 2026 CORE Biomedicine, a biotechnology company pioneering lineage-based precision oncology therapeutics, reported the completion of a $21 million Series A financing. The round is co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, alongside participation from InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., Suzhou Capital Group Co., Ltd., CD Capital, YuanBio Venture Capital, Vision Incubate Co., Ltd., and Root Venture Partners. CORE’s lineage-based approach is designed to identify and target core oncology drivers with precision while expanding the potential patient populations that may benefit from these novel therapies.

In addition to venture financing, CORE Biomedicine Japan, a wholly owned subsidiary, has been awarded a grant under the Strengthening Program for Pharmaceutical Startup Ecosystem, a highly competitive initiative run by the Japan Agency for Medical Research and Development (AMED) to accelerate innovative biotech companies and support Japan’s biopharma ecosystem. This grant supports CORE’s research and development activities while strengthening collaborations through partnerships with Japanese universities, hospitals and the overall biopharma community.

These resources will advance CORE’s lead programs through discovery and early clinical development. CORE is building an innovative precision medicine company by leveraging the rapidly evolving global biotech ecosystem.

"This venture financing and AMED’s support represent a major milestone for CORE Biomedicine and validate our vision for a new generation of oncology medicines," said Dr. Ping Zhu, Co-Founder and CEO of CORE Biomedicine. "We are grateful to our investors and partners as we advance our programs toward the clinic with the goal of bringing transformative therapies to patients globally."

"CORE Biomedicine’s lineage-based approach addresses a fundamental challenge in cancer biology that genomics alone cannot solve," said Makoto (Mark) Ohori, PhD, Partner and Chief Investment Officer, Life Sciences, UTokyo Innovation Platform Co., Ltd. "We are proud to co-lead this financing and look forward to supporting the CORE Biomedicine team as they advance their programs toward the clinic."

"Elikon Venture highly recognizes the CORE Biomedicine team for their distinctive insights and extensive R&D experience in oncology area. We are delighted to witness the company’s fast-growing trajectory. We look forward to collaborating with CORE Biomedicine to advance its cutting-edge drug pipeline and address unmet medical needs for global patients by delivering better clinical benefits."

(Press release, CORE Biomedicine, JUL 28, 2026, View Source [SID1234669471])

CORE Biomedicine Signs Exclusive Licensing Agreement with Eisai for Precision Oncology Programs

On July 28, 2026 CORE Biomedicine, an innovative drug discovery company developing next-generation precision medicines for broader populations of cancer patients, reported a licensing agreement with Eisai Co., Ltd., granting CORE exclusive global rights to develop and commercialize multiple preclinical oncology programs.

The licensed programs were originally discovered through research activities conducted by Eisai and its affiliates. CORE Biomedicine was established by experienced oncology drug development leaders to advance these innovative programs for patients with cancer worldwide.

Under the agreement, CORE has obtained exclusive, global rights to certain preclinical oncology programs that target key molecular drivers of various cancers. The licensed portfolio includes multiple programs spanning distinct targets and biological pathways. Together, these assets provide CORE with a broad foundation to build a next-generation precision medicine company focused on translating deep cancer biology into transformative therapies for patients.

"CORE was created to advance an exceptional portfolio of oncology programs grounded in deep cancer biology, precision medicine and lineage therapeutics," said Dr. Douglas McMillin, Co-Founder and Head of Business Development of CORE Biomedicine. "We believe these programs have tremendous potential to address significant unmet medical needs across multiple cancers, and we are committed to advancing them efficiently toward the clinic and ultimately to patients."

CORE is advancing multiple precision oncology programs to clinical development designed to deliver transformative therapies for patients with unmet medical need. The agreement enables the continued advancement of innovative oncology programs through CORE’s dedicated development strategy and commitment to precision medicine.

(Press release, CORE Biomedicine, JUL 28, 2026, View Source [SID1234669470])

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

On July 28, 2026 Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, reported the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study titled, "Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity in ERα+ breast cancer," reported anti-estrogenic and anti-cancer activity across multiple estrogen receptor-positive breast cancer models, including models harboring clinically relevant activating mutations in ESR1.

Publication Details

Journal: npj Breast Cancer
Publication Date: July 20, 2026
Article Title and Link: Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity in ERα+ breast cancer
Research Collaboration: Mayo Clinic and Atossa Therapeutics, Inc.

Summary

The investigators evaluated five previously uncharacterized compounds generated during the synthesis of (Z)-endoxifen – AT416E, AT416Z, AT402E, AT402Z and AT300 – alongside (Z)-endoxifen in a broad panel of laboratory assays. The studies assessed two- and three-dimensional tumor-cell growth, apoptosis, cell-cycle progression, migration, invasion, estrogen receptor transcriptional activity, gene-expression changes and activity in combination with the CDK4/6 inhibitor abemaciclib.
Several compounds demonstrated potent anti-estrogenic effects, and affected multiple anti-cancer processes including apoptosis, cell-cycle progression, migration, invasion and estrogen receptor-driven transcription.
In certain experimental settings and models, selected compounds combined with abemaciclib demonstrated additive to synergistic activity that was comparable to or greater than the activity observed with abemaciclib plus (Z)-endoxifen.
The compounds also showed activity in models containing activating ESR1 mutations, which are associated with endocrine resistance and recurrent or metastatic estrogen receptor-positive breast cancer.
RNA-sequencing analyses identified shared anti-estrogenic effects as well as distinct compound-specific transcriptional programs that may help differentiate the candidates.
The authors concluded that select compounds warrant further in vivo safety evaluation, as well as efficacy studies, including as potential second- or third-line approaches for recurrent disease. These findings are preclinical and do not establish safety or efficacy in patients.
"This publication expands the scientific foundation of our endoxifen platform and identifies additional compounds with compelling activity across difficult-to-treat estrogen receptor-positive breast cancer models," said Dr. Steven C. Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa Therapeutics. "Of particular interest is the activity observed in ESR1-mutant models and in combination with a CDK4/6 inhibitor. While these results are early and preclinical, we believe they provide a strong rationale for further evaluation of selected candidates as we continue to explore opportunities to address endocrine resistance and recurrent disease."

About Estrogen Receptor-Positive Breast Cancer

Estrogen receptor-positive breast cancer is the most common molecular subtype of breast cancer. Although endocrine therapies are effective for many patients, recurrence and late relapse remain important clinical challenges. Activating mutations in ESR1 can allow estrogen receptor signaling to continue despite estrogen deprivation and are a recognized mechanism of acquired resistance in advanced disease. New therapies capable of inhibiting estrogen receptor signaling in ESR1-mutant tumors, alone or in rational combinations, may help address this unmet need.

(Press release, Atossa Therapeutics, JUL 28, 2026, View Source [SID1234669469])

Ono Pharmaceutical partners with Phylo to embed agentic AI with every discovery scientist

On July 28, 2026 Ono Pharmaceutical Co., Ltd. (TYO: 4528, "Ono") and Phylo, Inc. ("Phylo") reported a collaboration that brings Biomni Lab, Phylo’s agentic AI platform for biomedical research, to Ono’s drug discovery scientists.

Founded in 1717 and headquartered in Osaka, Ono is a R&D-driven company dedicated to discovering innovative medicines for patients with serious diseases. Its therapies, including the pioneering cancer immunotherapy OPDIVO (nivolumab), have reached millions of patients worldwide. Ono has built its modern strategy on proactive, open innovation, including AI that shortens the path from idea to novel compound and improves the speed and success rate of discovery.

Phylo is a natural partner to augment Ono’s 300+ years of scientific expertise. Its Biomni Lab lets scientists collaborate with AI agents to complete complex, end-to-end workflows—from synthesizing experimental history and reasoning over internal data to designing experiments and executing computational biology. By incorporating Ono’s discovery expertise and historical data with Biomni Lab’s rigorous and scalable agentic AI platform, the Ono and Phylo partnership helps scientists move from questions to discoveries in a fraction of the time.

"We believe AI will become a core capability for drug discovery. With patients waiting for new medicines, there is an urgent need to help scientists move faster without compromising scientific rigor. Biomni Lab stood out because our researchers quickly adopted it and saw its potential to accelerate everyday discovery. We look forward to working with Phylo to explore how agentic AI can help bring new medicines to patients faster," said Seishi Katsumata, Corporate Officer / Executive Vice President, Discovery & Research of Ono.

"We believe drug discovery can be faster and more efficient with scientists working alongside AI agents. Ono’s discovery leadership across oncology, immunology & inflammation, and neurology makes them an ideal partner to demonstrate how this new way of working can accelerate breakthrough research," said Kexin Huang, Ph.D., Co-Founder & CEO of Phylo.

(Press release, Ono, JUL 28, 2026, View Source [SID1234669468])